Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03620578
Title DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HO152)
Acronym HO152
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stichting Hemato-Oncologie voor Volwassenen Nederland
Indications
Therapies
Age Groups: senior | adult
Covered Countries NLD | BEL


No variant requirements are available.